Overview

Ipilimumab 12-month Intensive Pharmacovigilance Protocol

Status:
Completed
Trial end date:
2015-02-01
Target enrollment:
0
Participant gender:
All
Summary
The primary objective of the protocol is to identify and describe observed adverse events (AEs) while on treatment with Ipilimumab for advanced melanoma in Venezuela during the study period
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Bristol-Myers Squibb
Collaborator:
JSS Medical Research Inc.
Treatments:
Antibodies, Monoclonal
Ipilimumab
Criteria
For more information regarding BMS clinical trial participation, please visit
www.BMSStudyConnect.com.

Inclusion Criteria:

- Age of 18 years or older on date of first dose of Ipilimumab

- Subjects who received at least 1 dose of Ipilimumab for the treatment of unresectable,
recurrent or metastatic melanoma in Venezuela

Exclusion Criteria:

- Subjects who received Ipilimumab as part of a clinical trial

- Subjects who received Ipilimumab for any indication other than local approval (ie,
unresectable or metastatic melanoma)